ASC30
Sources
registry, as of 2026-09-16Stale
https://clinicaltrials.gov/study/NCT07743463
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities. Overall status RECRUITING. Phases PHASE3. Lead sponsor Ascletis Pharma (China) Co., Limited. Enrollment 3003. Conditions Obesity; Overweight; Chronic Weight Management. Study ASC30-301 (AURORA-1) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesit
ClinicalTrials.gov NCT07743463 protocol and results modules
registry, as of 2026-09-16Stale
https://clinicaltrials.gov/study/NCT07743450
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes. Overall status RECRUITING. Phases PHASE3. Lead sponsor Ascletis Pharma (China) Co., Limited. Enrollment 1560. Conditions Obesity; Overweight; Chronic Weight Management; Type 2 Diabetes Mellitus. Study ASC30-302 (AURORA-2) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesit
ClinicalTrials.gov NCT07743450 protocol and results modules
registry, as of 2025-12-15Stale
https://clinicaltrials.gov/study/NCT07002905
A Study to Evaluate the Efficacy, Safety, and Tolerability in Participants With Obesity or Overweight With Weight-Related Comorbidities. Overall status COMPLETED. Phases PHASE2. Lead sponsor Ascletis Pharma (China) Co., Limited. Enrollment 125. Conditions Chronic Weight Management. This randomized, double-blind, placebo-controlled phase IIa study is designed to evaluate the efficacy, safety, and tolerability of ASC30 Tablets and ASC30 Tablets A1.
ClinicalTrials.gov NCT07002905 protocol and results modules
registry, as of 2026-06-26Stale
https://clinicaltrials.gov/study/NCT06679959
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASC30 Injection in Participants With Obesity. Overall status COMPLETED. Phases PHASE1,PHASE2. Lead sponsor Ascletis Pharma (China) Co., Limited. Enrollment 115. Conditions Chronic Weight Management. This randomized, double-blind, placebo-controlled single ascending dose (SAD)/ multiple ascending dose (MAD) study is designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ASC30 injection
ClinicalTrials.gov NCT06679959 protocol and results modules
registry, as of 2025-05-20Stale
https://clinicaltrials.gov/study/NCT06680440
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of ASC30 Tablets and ASC30 Tablets A1 in Participants With Obesity. Overall status COMPLETED. Phases PHASE1. Lead sponsor Ascletis Pharma (China) Co., Limited. Enrollment 72. Conditions Weight Management. This is a phase I, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, efficacy, food effect of ASC30 Tablets or ASC30 Tablets A1 in participants with obesity.
ClinicalTrials.gov NCT06680440 protocol and results modules